Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Equities researchers at Svb Leerink upped their Q3 2019 EPS estimates for Ionis Pharmaceuticals in a research report issued on Thursday, October 17th. Svb Leerink analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.18) for the quarter, up from their previous forecast of ($0.22). Svb Leerink also issued estimates for Ionis Pharmaceuticals’ Q4 2019 earnings at $1.22 EPS, FY2019 earnings at $1.68 EPS and FY2020 earnings at $0.49 EPS.
A number of other analysts have also commented on the company. TheStreet lowered Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Thursday, August 8th. Evercore ISI set a $76.00 price target on Ionis Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $62.00 price target on the stock in a research note on Tuesday. Sanford C. Bernstein raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research note on Tuesday, September 10th. Finally, BidaskClub lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $75.27.
IONS opened at $54.73 on Monday. The company has a quick ratio of 9.93, a current ratio of 10.01 and a debt-to-equity ratio of 0.45. The firm has a market cap of $7.84 billion, a P/E ratio of 18.49, a PEG ratio of 15.94 and a beta of 1.95. Ionis Pharmaceuticals has a 52 week low of $45.48 and a 52 week high of $86.58. The business’s fifty day simple moving average is $60.82 and its 200 day simple moving average is $66.59.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.26. The business had revenue of $164.00 million for the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The business’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) earnings per share.
In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 22,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $71.52, for a total value of $1,573,440.00. Following the sale, the chairman now directly owns 79,634 shares of the company’s stock, valued at approximately $5,695,423.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.40% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Advisory Services Network LLC raised its holdings in shares of Ionis Pharmaceuticals by 38.5% in the 2nd quarter. Advisory Services Network LLC now owns 907 shares of the company’s stock worth $58,000 after purchasing an additional 252 shares during the period. Daiwa Securities Group Inc. raised its holdings in shares of Ionis Pharmaceuticals by 567.4% in the 2nd quarter. Daiwa Securities Group Inc. now owns 5,840 shares of the company’s stock worth $375,000 after purchasing an additional 4,965 shares during the period. Polianta Ltd purchased a new position in shares of Ionis Pharmaceuticals in the 2nd quarter worth about $1,079,000. Pacer Advisors Inc. purchased a new position in shares of Ionis Pharmaceuticals in the 2nd quarter worth about $1,307,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Ionis Pharmaceuticals by 5.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 616,513 shares of the company’s stock worth $39,624,000 after purchasing an additional 33,997 shares during the period. Institutional investors own 88.98% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Featured Article: What is a recession?
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.